A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Prior treatment

• Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling
• Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label
• Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program

Other

• Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life

• Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
  • Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC
  • Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated
  • Extensive-stage small cell lung cancer (ES-SCLC) not previously treated
  • Advanced or unresectable HCC not previously treated with systemic therapy
• Should not have received \> 4 prior cycles of IV Atezolizumab